Technical Development of Cardiovascular Magnetic Resonance Imaging
Peripheral Artery Disease
About this trial
This is an interventional treatment trial for Peripheral Artery Disease focused on measuring Blood Flow, Revascularization, Image Fusion, Fluoroscopy, MRI, Chronic Total Occlusion of Arteries, Claudication, Safety, Atherosclerosis, Cardiovascular Disease
Eligibility Criteria
INCLUSION CRITERIA FOR ALL ARMS OF THE PROTOCOL: Subjects with known or suspected cardiovascular disease will be eligible for participation in this protocol. The subject is eligible under the following conditions: Subject's age is greater than 18 years of age. Expected to undergo, or having undergone, a clinically-indicated diagnostic or therapeutic catheterization procedure or MRI angiogram procedure. Additional Inclusion Criteria for Section #4: Magnetic Resonance Imaging of Peripheral Arterial Atherosclerosis -Known or suspected peripheral artery occlusion. EXCLUSION CRITERIA FOR ALL ARMS OF THE PROTOCOL: Subjects with absolute contraindications to MRI scanning will be excluded. These contraindications include subjects with the following devices: Implanted cardiac pacemaker or defibrillator Central nervous system aneurysm clips Implanted neural stimulator Cochlear implant Ocular foreign body (e.g. metal shavings) Insulin pump Metal shrapnel or bullet. When subjects can provide evidence that their implanted device is labeled compatible with MRI, exceptions to the above exclusions can be made and recorded in the note. Furthermore, the FOLLOWING SUBJECT GROUPS WILL BE EXCLUDED because of the administration of MRI CONTRAST AGENTS: Pregnant women (Subjects who are uncertain as to whether they are pregnant will be required to have a screening urine or blood pregnancy test) or Lactating Women. Subjects with hemoglobinopathies Subjects with renal disease (eGFR[R] less than 30 mL/min/1.73m(2)) Glomerular filtration rate will be estimated using the MDRD 2005 revised study formula: eGFR (mL/min/1.73m (2)) equal 175 x (standardized Scr) (-1.154) x (age) (-0.203) x 0.742 (if the subject is female) or x 1.212 (if the subject is black) However, if the eGFR less than 30 mL/min/1.73m(2) and gadolinium contrast exposure is thought likely to reduce the overall risk of the medically necessary interventional procedure in Specific Aim number 2, then with informed consent and the concurrence of the attending physician, the patient may be enrolled in the study. This would be documented in the medical record, and the IRB would be notified. Additional Exclusion Criteria for Section #2: Lower Extremity Perfusion Measures A patent autologous or prosthetic bypass graft that would require compression during arterial occlusion to induce reactive hyperemia. This exclusion is intended to avoid graft injury and possible thrombosis. If an old graft is known to be non-functional, from radiocontrast or MRI angiography, then this exclusion does not apply. A patent intravascular stent in a territory that would be compressed during arterial occlusion to induce reactive hyperemia. This exclusion is intended to avoid theoretical stent crush or fracture. If the stented vessel is known to be completely occluded, from radiocontrast or MRI angiography, then this exclusion does not apply. However, occlusive cuffs may be placed above or below stent devices to avoid this theoretical complication. Active deep vein thrombosis of the lower extremity based on clinical findings.
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike